CLINTON, N.J., July 8 /PRNewswire/ -- Ikaria, Inc. today announced that Craig Tooman will join Ikaria as Senior Vice President and Chief Financial Officer (CFO). In this role, Mr. Tooman will be responsible for all financial functions of the company, as well as for information technology services. Mr. Tooman succeeds Elizabeth Larkin, who left the company in March to pursue other interests. He will assume his new role at the beginning of August.
“I am delighted that Craig will join us in this key executive role, and am confident that we will benefit greatly from his knowledge and experience in effectively managing the financial aspects of our business,” commented Daniel Tasse, Chairman and CEO of Ikaria. “I believe that Craig’s expertise -- combined with our product pipeline and commercial capabilities -- will help us achieve our vision of becoming a leader in critical care. I also wish to thank Liz for building a strong foundation from which we can build.”
Mr. Tooman has over 20 years of experience in the pharmaceutical industry, and joins Ikaria from Enzon Pharmaceuticals, where he was Executive Vice President of Finance and CFO since 2005. Prior to joining Enzon, he served as Senior Vice President of Strategic Planning and Corporate Communications at ILEX Oncology, Inc., which was acquired by Genzyme in 2004. He also played a significant role in the 2001 merger between Pharmacia & Upjohn and Monsanto that created the Pharmacia Corporation, having served in various positions within its predecessor companies Pharmacia & Upjohn and The Upjohn Company. Mr. Tooman holds an MBA from the University of Chicago, and a BA from Kalamazoo College.
About Ikaria, Inc.
Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients. The company’s lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering, is the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. INOtherapy also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. Ikaria acquired the North American and Australian rights to LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide license to IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The company also has a number of investigational compounds in development. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit www.ikaria.com.
SOURCE Ikaria, Inc.
